Table of Contents
Overview
MGA acts as a transcriptional repressor and interacts with MYC, a well-known oncogene. Mutations in MGA have been described in DLBCL.1 One study suggested MGA mutations were more common in DLBCLs in patients of African ancestry.2 The mutation pattern in MGA is consistent with a role as a tumour suppressor gene.
Experimental Evidence
Driver mutations affecting this gene in DLBCL have been experimentally demonstrated to cause a reduction or loss of function (LOF).3
Relevance tier by entity
Cannot include /table1_MGA.md - does not exist yet
Mutation incidence in large patient cohorts (GAMBL reanalysis)
DLBCL
Cannot include /DLBCL_MGA.md - does not exist yet
Mutation pattern and selective pressure estimates
Cannot include /dnds_MGA.md - does not exist yet
Cannot include /browser_MGA.md - does not exist yet
Expression
Cannot include /mermaid_MGA.md - does not exist yet
References
1.
Jallades L, Baseggio L, Sujobert P, Huet S,
Chabane K, Callet-Bauchu E, Verney A, Hayette S, Desvignes JP, Salgado
D, Levy N, Béroud C, Felman P, Berger F, Magaud JP, Genestier L, Salles
G, Traverse-Glehen A. Exome sequencing identifies recurrent
BCOR alterations and the absence of KLF2,
TNFAIP3 and MYD88 mutations in splenic diffuse
red pulp small B-cell lymphoma.
Haematologica. 2017 Oct;102(10):1758–1766. PMCID: PMC5622860
2.
Reddy A, Zhang J, Davis NS, Moffitt AB, Love
CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg
ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W,
Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y,
Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O,
Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB,
Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava
G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn
A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T,
Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional
Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017
Oct;171(2):481–494.e15. PMCID: PMC5659841
3.
De
Paoli L, Cerri M, Monti S, Rasi S, Spina V, Bruscaggin A, Greco M,
Ciardullo C, Famà R, Cresta S, Maffei R, Ladetto M, Martini M, Laurenti
L, Forconi F, Marasca R, Larocca LM, Bertoni F, Gaidano G, Rossi D. MGA, a
suppressor of MYC, is recurrently inactivated in high risk
chronic lymphocytic leukemia. Leuk Lymphoma. 2013
May;54(5):1087–1090.